Can a three-drug cocktail outsmart resistant prostate cancer?

NCT ID NCT04471974

Ongoing Disease control Sponsor: Rahul Aggarwal Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether combining three drugs—ZEN-3694, enzalutamide, and pembrolizumab—can shrink tumors or lower PSA levels in men with metastatic castration-resistant prostate cancer that has worsened despite prior treatment. ZEN-3694 blocks a protein that fuels cancer growth, enzalutamide blocks testosterone signals, and pembrolizumab helps the immune system attack cancer cells. The study aims to see if this triple approach works better than current options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a triple combination of the BET bromodomain inhibitor ZEN-3694, enzalutamide, and pembrolizumab
What this could lead to: If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits are uncertain. Combining three drugs may also increase the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate small cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC PROSTATE ADENOCARCINOMA METASTATIC PROSTATE SMALL CELL CARCINOMA STAGE IV PROSTATE CANCER AJCC V8 STAGE IVA PROSTATE CANCER AJCC V8 STAGE IVB PROSTATE CANCER AJCC V8

Contacts and locations

Show contact details

Locations

University of California, San Francisco

San Francisco, California, 94143, United States
University of Chicago

Evergreen Park, Illinois, 60805, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.